Page last updated: 2024-12-05

picotamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Picotamide is a synthetic compound with the chemical formula C14H16N2O2. It is a derivative of benzamide and is known for its potential anti-inflammatory and anti-depressant effects. Its synthesis involves a multi-step process starting from aromatic compounds. Picotamide has been shown to inhibit the production of inflammatory cytokines and to modulate neurotransmitter activity in the brain, suggesting its potential therapeutic applications. Researchers are studying its effects on various conditions, including depression, anxiety, and inflammatory bowel disease. Picotamide's unique pharmacological profile and potential therapeutic benefits make it a subject of ongoing research.'

picotamide: has anticoagulant & fibrinolytic properties; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4814
CHEMBL ID1257015
CHEBI ID93175
SCHEMBL ID137025
MeSH IDM0057978

Synonyms (75)

Synonym
BRD-K67277431-002-03-0
picotamide
32828-81-2
nsc304384
nsc-304384
g-137
EU-0101003
n,n'-bis(3-pyridinylmethyl)-4-methoxy-1,3-benzenedicarboxamide
brn 0499268
4-methoxy-n,n'-bis(3-pyridinylmethyl)-1,3-benzenedicarboxamide
1,3-benzenedicarboxamide, n,n'-bis(3-pyridinylmethyl)-4-methoxy-
g 137
n,n'-bis(3-picolyl)-4-methoxyisophthalamide
n,n'-bis(3-pyridylmethyl)-4-methoxyisophthalamide
4-methoxy-n,n'-bis(3-pyridylmethyl)isophthalamide
isophthalamide, 4-methoxy-n,n'-bis(3-pyridylmethyl)-
4-methoxy-n,n'-bis(3-pyridylmethyl)isophthaldiamide
einecs 251-245-7
NCGC00015847-01
lopac-p-8477
plactidil (tn)
picotamide (ban)
D07140
BPBIO1_000152
PRESTWICK3_000119
BSPBIO_000138
SPBIO_002077
PRESTWICK0_000119
PRESTWICK1_000119
LOPAC0_001003
PRESTWICK2_000119
NCGC00094297-01
NCGC00094297-02
NCGC00015847-02
L013375
P 8477
HMS2090L18
NCGC00015847-04
4-methoxy-1-n,3-n-bis(pyridin-3-ylmethyl)benzene-1,3-dicarboxamide
HMS3263I07
CHEMBL1257015
CCG-205083
nsc 304384
unii-654g2vci4q
picotamide [inn:ban]
654g2vci4q ,
NCGC00015847-03
NCGC00015847-05
FT-0630565
LP01003
picotamide [who-dd]
picotamide [mi]
1,3-benzenedicarboxamide, 4-methoxy-n,n'-bis(3-pyridinylmethyl)-
picotamide [mart.]
1,3-benzenedicarboxamide, 4-methoxy-n1,n3-bis(3-pyridinylmethyl)-
SCHEMBL137025
tox21_501003
NCGC00261688-01
DTXSID40186498
CHEBI:93175
4-methoxy-n1,n3-bis(3-pyridinylmethyl)benzene-1,3-dicarboxamide
bdbm50103507
J-018896
sr-01000076086
SR-01000076086-1
SBI-0050976.P002
4-methoxy-n1,n3-bis(pyridin-3-ylmethyl)isophthalamide
(s)-(-)-2-methoxypropionicacid
DB13327
1085306-93-9
Q1235921
SDCCGSBI-0050976.P003
MS-26107
gtpl11379
AKOS040759696

Research Excerpts

Overview

Picotamide is a new antiaggregating agent influencing the platelet prostaglandin pathway through an inhibition of thromboxane A2 (TXA2) synthesis and a competitive antagonism of platelet TXA2 receptors.

ExcerptReferenceRelevance
"Picotamide is a thromboxane A"( Picotamide inhibits a wide spectrum of agonist-induced smooth muscle contractions in porcine renal interlobar and coronary arteries.
Hennenberg, M; Huang, R; Li, B; Liu, Y; Stief, CG; Wang, R, 2021
)
3.51
"Picotamide is an antiplatelet drug with a dual inhibitory action. "( A review of picotamide in the reduction of cardiovascular events in diabetic patients.
Celestini, A; Violi, F, 2007
)
2.16
"Picotamide is a new antiaggregating agent influencing the platelet prostaglandin pathway through an inhibition of thromboxane A2 (TXA2) synthesis and a competitive antagonism of platelet TXA2 receptors. "( Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood.
Anfossi, G; Cavalot, F; Massucco, P; Mattiello, L; Mularoni, EM; Parisi, S; Russo, I; Trovati, M, 1995
)
2.02
"Picotamide is a new anti-platelet drug sharing a dual anti-thromboxane activity: inhibition of thromboxane A2 synthase and thromboxane A2 receptor antagonism."( Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study.
Milani, M; Pogliani, E,
)
1.16
"Picotamide is an antiplatelet drug which inhibits thromboxane A2 (TxA2) synthase and antagonizes TxA2 receptors. "( Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study.
Longoni, A; Maderna, M; Milani, M, 1996
)
2.13
"Picotamide is a dual TxA2 receptor antagonist/TxA2 synthetase inhibitor. "( Mechanism of the persisting TxA2 receptor antagonism by picotamide.
Gazzaniga, PP; Parisi, S; Pesciotti, M; Pignatelli, P; Pulcinelli, FM; Sebastiani, S, 1997
)
1.99
"Picotamide is a platelet antiaggregant that acts through both inhibition of thromboxane synthase and thromboxane-receptor antagonism."( Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor.
Ambrosioni, E; Malini, PL; Milani, M; Strocchi, E; Zanardi, M, 1997
)
1.02
"Picotamide is a dual thromboxane (Tx) A2 receptor antagonist/Tx synthase inhibitor although some observations suggest an anti-vasoconstrictor effect independent of TxA2 inhibition/antagonism. "( Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism.
Gresele, P; Nathan, M; Page, CP; Spina, D; Tallarida, RJ; Vezza, R, 1997
)
1.99
"Picotamide is an antiplatelet drug with a peculiar dual mechanism of action: it inhibits thromboxane A2 synthase and antagonizes the pharmacological responses mediated by thromboxane A2 receptor. "( Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes.
Casagrande, C; Corsini, A; Fumagalli, R; Quarato, P; Ratti, S, 1998
)
3.19
"Picotamide is an antiplatelet agent given by mouth as monohydrate (PICOW) (Plactidil) in thrombo-embolic disorders. "( Physical characterization of picotamide monohydrate and anhydrous picotamide.
Bettinetti, G; Faucci, MT; Mura, P; Negri, A; Sorrenti, M, 1999
)
2.04
"Picotamide appears to be an antiplatelet drug that reduces TxA2 synthesis without affecting cyclo-oxygenase activity."( Inhibition by picotamide of thromboxane production in vitro and ex vivo.
Alessandri, C; Balsano, F; Ghiselli, A; Iuliano, L; Praticò, D; Violi, F, 1988
)
1.36

Effects

ExcerptReferenceRelevance
"1. Picotamide has been shown to interfere competitively with the thromboxane A2 (TxA2) platelet receptor. "( Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor.
Abbate, R; Cecioni, I; Colella, A; Gensini, GF; Modesti, PA; Neri Serneri, GG, 1991
)
0.9

Actions

Picotamide was shown to inhibit platelet binding of thromboxane A2 (TxA2)-mimetics and to cause a reduction of TxA2 platelet receptors after in vivo administration. Picotamide did not inhibit potassium-induced contractions, thus excluding aspecific effects on vascular smooth muscle.

ExcerptReferenceRelevance
"1. Picotamide was shown to inhibit platelet binding of thromboxane A2 (TxA2)-mimetics and to cause a reduction of TxA2 platelet receptors after in vivo administration. "( Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist.
Cecioni, I; Colella, A; Costoli, A; Modesti, PA; Neri Serneri, GG; Paniccia, R, 1994
)
1.17
"Picotamide did not increase the risk of bleeding in these patients, while at the same time, no thrombotic events were observed during the 1-year treatment."( Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study.
Milani, M; Pogliani, E,
)
1.16
"Picotamide did not inhibit potassium-induced contractions, thus excluding aspecific effects on vascular smooth muscle."( Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism.
Gresele, P; Nathan, M; Page, CP; Spina, D; Tallarida, RJ; Vezza, R, 1997
)
1.27
"Picotamide did not inhibit the formation of TxB2 in serum at any of the doses tested (100 to 750 mg/kg i.p.) while it did enhance significantly PGI2-synthesis from mice aortae and, even more, from mice lungs."( Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression.
Alberti, P; Corona, C; Gresele, P; Nenci, GG, 1990
)
2.44

Treatment

Picotamide-treated platelets favour the formation of PGI2 by aspirinated endothelial cells. The drug appears to exert a direct stimulatory effect on P GI2-synthesis, at least at high concentrations.

ExcerptReferenceRelevance
"Picotamide treatment was well tolerated and no major side-effects were observed during the study periods."( Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study.
Cocozza, M; Coto, V; Milani, M; Oliviero, U,
)
1.13
"Picotamide treatment caused a decrease of resting thromboxane B2 and endothelin-1 concentrations, produced an improvement of the vascular function as seen by the increase of vascular parameters reported, and attenuated the ischemic treadmill-induced increase of thromboxane B2, but not of endothelin-1."( Effects of picotamide on release of endothelin-1, thromboxane and prostacycline after treadmill stress in patients with peripheral artery disease.
Bonaiuto, M; Campo, GM; Castaldo, M; Cinquegrani, M; D'Arrigo, D; Giordano, G; Imbalzano, E; Saitta, A; Sardo, A; Squadrito, F, 1998
)
1.41
"Picotamide-treated platelets also favour the formation of PGI2 by aspirinated endothelial cells; in addition, the drug appears to exert a direct stimulatory effect on PGI2-synthesis, at least at high concentrations."( Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
Arnout, J; Deckmyn, H; Gresele, P; Nenci, GG; Vermylen, J, 1989
)
1.24
"Treatment with picotamide significantly reduced circulating platelet aggregates, beta-TG and TxB2 levels, without change of 6-keto-PGF-alpha values, with reduction of F VIII-C and slight increase of plasminogen and ATIII levels."( [Evaluation of arteriolar reactivity and blood coagulation parameters during picotamide treatment].
Bonaiuto, M; Mileto, A; Saitta, A,
)
0.7

Toxicity

ExcerptReferenceRelevance
" This observational long-term trial shows that picotamide treatment in patients with thrombocytosis at high risk of thrombotic events is safe and well tolerated."( Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study.
Milani, M; Pogliani, E,
)
0.7

Compound-Compound Interactions

ExcerptReferenceRelevance
" We compared the safety and efficacy of two different antiplatelet drugs, aspirin (asa) and picotamide (pico)--a dual antithromboxane agent--in combination with low-intensity oral anticoagulation with warfarin or acenocoumarol in acute myocardial infarction (AMI)."( Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial.
Corsini, G; Milani, M; Vetrano, A, 1999
)
0.84

Dosage Studied

ExcerptRelevanceReference
" for 10 days to 10 patients with aortic or mitral valve prostheses did not modify significantly either the level of anticoagulation or the mean daily dosage of warfarin."( [Picotamide does not interfere with the anticoagulant activity of warfarin in patients wearing heart valve prostheses].
Gresele, P; Migliacci, R; Nenci, GG; Parise, P; Ruina, A; Viola, E, 1990
)
1.19
" The patient, treated for several days with porcine Ca-heparin at a dosage of 10,000 IU/day, presented severe thrombocytopenia (Plt 36 x 10(9)/L), intermittent right leg ischemia, and a positive heparin-induced platelet aggregation assay."( Heparin-induced thrombocytopenia with arterial thrombosis: an unusual case.
Corradi, F; Di Natale, M; Fiusti, R; Grassi, M; Lai, F,
)
0.13
" For each aggregating agent, ED50 value (agonist concentration necessary to induce a maximal aggregation of 50%) was determined in control samples and following addition of different picotamide concentrations on the basis of dose-response curves."( Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood.
Anfossi, G; Cavalot, F; Massucco, P; Mattiello, L; Mularoni, EM; Parisi, S; Russo, I; Trovati, M, 1995
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
D(1A) dopamine receptorHomo sapiens (human)Potency5.80450.02245.944922.3872AID488982
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency0.19010.134610.395030.1313AID1347049
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency19.01150.425612.059128.1838AID504536
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.16230.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.16231.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)636.50000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)441.00000.11007.190310.0000AID1209455
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1766293Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of ADP-induced aggregation at 1.3 uM pre-treated for 2 mins followed by ADP addition by Born turbidimetric method relative to control2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1353591Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation by cytometry2018European journal of medicinal chemistry, Mar-10, Volume: 147Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1766294Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of ADP-induced aggregation pre-treated for 2 mins followed by ADP addition by Born turbidimetric method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID695150Antiplatelet activity against rat platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation after 2 mins by Born test method2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides.
AID1766295Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of arachidonic acid-induced aggregation at 1.3 uM pre-treated for 2 mins followed by ADP addition by Born turbidimetric method relative to control2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1766297Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of collagen-induced aggregation at 1.3 uM pre-treated for 2 mins followed by ADP addition by Born turbidimetric method relative to control2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents.
AID1766296Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of arachidonic acid-induced aggregation pre-treated for 2 mins followed by ADP addition by Born turbidimetric method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Synthesis, in vitro cytotoxicity and biological evaluation of twenty novel 1,3-benzenedisulfonyl piperazines as antiplatelet agents.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (93)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (15.05)18.7374
1990's44 (47.31)18.2507
2000's14 (15.05)29.6817
2010's14 (15.05)24.3611
2020's7 (7.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.60 (24.57)
Research Supply Index4.86 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (28.00%)5.53%
Reviews5 (5.00%)6.00%
Case Studies3 (3.00%)4.05%
Observational0 (0.00%)0.25%
Other64 (64.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]